Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

  • Email
  • Help

Document details

Download document Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
Reference number EMA/CHMP/BWP/247713/2012
Status draft: consultation closed
First published 31/05/2012
Last updated 31/05/2012

Summary

This guideline lays down the quality requirements for a biological medicinal product claiming to be similar to another one already marketed. It addresses the requirements regarding manufacturing processes, the comparability exercise for quality, considering the choice of reference medicinal product, analytical methods, physicochemical characterisation, biological activity, purity and quality attributes for relevant specifications of the similar biological medicinal product.